

## Ruplizumab

|           |   |
|-----------|---|
| Cat. No.: | HY-P99315   |
| CAS No.:  | 220651-94-5   |
| Target:   | TNF Receptor  |
| Pathway:  | Apoptosis   |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

#### Description

Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research<sup>[1]</sup>.

### REFERENCES

[1]. Chris Chamberlain, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. *Ann Rheum Dis.* 2017 Nov;76(11):1837-1844.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA